Journal article
O. O. Shiyanbola, B. L. Kaiser, G. R. Thomas, A. Tarfa
Research Involvement and Engagement, vol. 7(1), 2021
Research Involvement and Engagement, vol. 7(1), 2021
Cite
Cite
APA
Click to copy
Shiyanbola, O. O., Kaiser, B. L., Thomas, G. R., & Tarfa, A. (2021). Preliminary engagement of a patient advisory board of African American community members with type 2 diabetes in a peer-led medication adherence intervention. Research Involvement and Engagement, 7(1). https://doi.org/10.1186/s40900-020-00245-y
Chicago/Turabian
Click to copy
Shiyanbola, O. O., B. L. Kaiser, G. R. Thomas, and A. Tarfa. “Preliminary Engagement of a Patient Advisory Board of African American Community Members with Type 2 Diabetes in a Peer-Led Medication Adherence Intervention.” Research Involvement and Engagement 7, no. 1 (2021).
MLA
Click to copy
Shiyanbola, O. O., et al. “Preliminary Engagement of a Patient Advisory Board of African American Community Members with Type 2 Diabetes in a Peer-Led Medication Adherence Intervention.” Research Involvement and Engagement, vol. 7, no. 1, 2021, doi:10.1186/s40900-020-00245-y.
BibTeX Click to copy
@article{shiyanbola2021a,
title = {Preliminary engagement of a patient advisory board of African American community members with type 2 diabetes in a peer-led medication adherence intervention},
year = {2021},
issue = {1},
journal = {Research Involvement and Engagement},
volume = {7},
doi = {10.1186/s40900-020-00245-y},
author = {Shiyanbola, O. O. and Kaiser, B. L. and Thomas, G. R. and Tarfa, A.}
}
Abstract
The Peers Supporting Health Literacy, Self-efficacy, Self-Advocacy, and Adherence (Peers LEAD) program is a culturally tailored educational-behavioral 8-week intervention that addressed psychosocial and sociocultural barriers to diabetes medication adherence in African Americans. A brief 3-week version of the Peers LEAD intervention used a community engagement approach to examine the feasibility and acceptability of the intervention amongst patient stakeholders.
African Americans who were adherent to their diabetes medicines were paired with those who were non-adherent to their medicines. Together, they participated in the group and phone-based medication adherence intervention. Input from this brief intervention was important for the design of the remainder weeks of the 8-week program. The intervention targeted negative beliefs about diabetes, use of diabetes medicines, and offering culturally tailored peer support to improve medication adherence in African Americans. To receive input in the development and implementation of the program, we worked with community advisors and a peer ambassador board of African Americans who were adherent to their diabetes medicines. The peer ambassador board and community advisors reviewed intervention materials to ensure they were understandable and appropriate for the community. As well, they provided feedback on the process for intervention delivery.
African Americans who were adherent to their diabetes medicines were paired with those who were non-adherent to their medicines. Together, they participated in the group and phone-based medication adherence intervention. Input from this brief intervention was important for the design of the remainder weeks of the 8-week program. The intervention targeted negative beliefs about diabetes, use of diabetes medicines, and offering culturally tailored peer support to improve medication adherence in African Americans. To receive input in the development and implementation of the program, we worked with community advisors and a peer ambassador board of African Americans who were adherent to their diabetes medicines. The peer ambassador board and community advisors reviewed intervention materials to ensure they were understandable and appropriate for the community. As well, they provided feedback on the process for intervention delivery.
The active engagement of the peer ambassador board and community advisors led to a revised intervention process and materials for a medication adherence program for African Americans with type 2 diabetes.
